Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)

NCT01377922 is registered in ClinicalTrials.gov with Catalyst Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01377922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01377922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Placebo-controlled, Randomized Discontinuation Study Followed by Open-label Extension Evaluating Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)
Lead sponsor
Catalyst Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2011
Completion date
July 31, 2016
Enrollment
38 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

lambert eaton myasthenic syndrome